Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

Inclusion Criteria: * Written informed consent for all study according to local regulatory requirements prior to beginning specific protocol procedures. * Complete baseline documentation must be sent to GBG Forschungs GmbH. * Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration alone is not sufficient. Incisional biopsy is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint. * Tumor lesion in the breast with a palpable size of \>= 2 cm or a sonographical size of \>= 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. * Patients must be in the following stages of disease: cT3 or cT2 or cT1c and cN+ or cT1c and pNSLN+. * In patients with multifocal or multicentric breast cancer, the largest lesion should be evaluated. * Centrally confirmed triple negative or luminal B/HER2-normal subtype. ER- and PgR-negative defined as \<1% stained cells. HER-2 negative defined as IHC 0+, 1+ or IHC 2+ and FISH/SISH/CISH (ratio \<2.0) negative. Luminal B defined as ER and/or PgR + and \> 14% Ki-67 stained cells. The formalin-fixed, paraffin-embedded (FFPE) breast tissue block from the diagnostic core biopsy has therefore to be sent to the Dept. of Pathology at the Charité, Berlin prior to randomization. * Age \>= 18 years. * Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 o…